Ivermectin as a novel malaria control tool: Getting ahead of the resistance curse.


Journal

Acta tropica
ISSN: 1873-6254
Titre abrégé: Acta Trop
Pays: Netherlands
ID NLM: 0370374

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 07 04 2023
revised: 14 06 2023
accepted: 16 06 2023
medline: 23 10 2023
pubmed: 24 6 2023
entrez: 23 6 2023
Statut: ppublish

Résumé

Reduction in malaria clinical cases is strongly dependent on the ability to prevent Anopheles infectious bites. Vector control strategies using long-lasting insecticidal nets and indoor residual spraying with insecticides have contributed to significantly reduce the incidence of malaria in many endemic countries, especially in the Sub-Saharan region. However, global progress in reducing malaria cases has plateaued since 2015 mostly due to the increased insecticide resistance and behavioral changes in Anopheles vectors. Additional control strategies are thus required to further reduce the burden of malaria and contain the spread of resistant and invasive Anopheles vectors. The use of endectocides such as ivermectin as an additional malaria control tool is now receiving increased attention, driven by its different mode of action compared to insecticides used so far and its excellent safety record for humans. In this opinion article, we discuss the advantages and disadvantages of using ivermectin for malaria control with a focus on the risk of selecting ivermectin resistance in malaria vectors. We also highlight the importance of understanding how ivermectin resistance could develop in mosquitoes and what its underlying mechanisms and associated molecular markers are, and propose a research agenda to manage this phenomenon.

Identifiants

pubmed: 37352998
pii: S0001-706X(23)00160-2
doi: 10.1016/j.actatropica.2023.106973
pii:
doi:

Substances chimiques

Ivermectin 70288-86-7
Insecticides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106973

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

André B Sagna (AB)

MIVEGEC, University of Montpellier, IRD, CNRS, Montpellier, France. Electronic address: andre.sagna@ird.fr.

Lamidi Zéla (L)

Centre International de Recherche-Développement sur l'Elevage en zone Subhumide, Bobo-Dioulasso, Burkina Faso.

Cheick Oumar W Ouedraogo (COW)

Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Centre National de Recherche Scientifique et Technologique, Bobo-Dioulasso, Burkina Faso.

Sié H Pooda (SH)

Centre International de Recherche-Développement sur l'Elevage en zone Subhumide, Bobo-Dioulasso, Burkina Faso; Université de Dédougou, Dédougou, Burkina Faso.

Angélique Porciani (A)

MIVEGEC, University of Montpellier, IRD, CNRS, Montpellier, France.

Joanna Furnival-Adams (J)

ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain.

Paula Lado (P)

Center for Vector-borne Infectious Diseases, Colorado State University, Fort Collins, CO, USA.

Anyirékun F Somé (AF)

Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Centre National de Recherche Scientifique et Technologique, Bobo-Dioulasso, Burkina Faso.

Cédric Pennetier (C)

MIVEGEC, University of Montpellier, IRD, CNRS, Montpellier, France.

Carlos J Chaccour (CJ)

ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Madrid, Spain; Universidad de Navarra, Pamplona, Spain.

Roch K Dabiré (RK)

Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Centre National de Recherche Scientifique et Technologique, Bobo-Dioulasso, Burkina Faso.

Karine Mouline (K)

MIVEGEC, University of Montpellier, IRD, CNRS, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH